AWM
CYTK icon

Abound Wealth Management’s Cytokinetics CYTK Stock Holding History

Abound Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14
Closed -$1.17K – 1316
2023
Q4 		$1.17K Buy
14
+3
+27% +$109 ﹤0.01% 744
2023
Q3 		$325 Hold
11
– – ﹤0.01% 986
2023
Q2 		$359 Buy
+11
New +$407 ﹤0.01% 977

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Abound Wealth Management's CYTK Position: Q1 2024 in Review

Abound Wealth Management sold out of Cytokinetics (CYTK) in Q1 2024, closing a stake of 14 shares — an estimated $1.17K sold.

Abound Wealth Management first reported a position in CYTK in Q2 2023 and held it in 3 quarters. The position peaked at $1.17K in Q4 2023. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

  • Abound Wealth Management reported no remaining Cytokinetics position as of Q1 2024 after selling out during the quarter.
  • Abound Wealth Management sold 14 Cytokinetics shares in Q1 2024, an estimated $1.17K.
  • Abound Wealth Management first reported a position in Cytokinetics in Q2 2023 and held it in 3 quarters.
  • Abound Wealth Management's Cytokinetics position peaked at $1.17K in Q4 2023.
  • 390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Abound Wealth Management's 13F filing for Q1 2024, filed 8 Aug 2024.